934828-12-3
934828-12-3
Chemical Structure
Zabadinostat
Synonym(s): CXD101
- CAS No.: 934828-12-3
- Formula:C24H29N5O
- Molecular Weight:403.52
IUPAC Name: N-(2-aminophenyl)-4-(1-((1,3-dimethyl-1H-pyrazol-4-yl)methyl)piperidin-4-yl)benzamide
InChIKey: JHDZMASHNBKTPS-UHFFFAOYSA-N
SMILES: O=C(NC1=C(N)C=CC=C1)C2=CC=C(C3CCN(CC4=CN(C)N=C4C)CC3)C=C2
Biological Activity: Zabadinostat (CXD101) is a potent, selective and orally active class I HDAC inhibitor with IC50s of 63 nM, 570 nM and 550 nM for HDAC1, HDAC2 and HDAC3, respectively. Zabadinostat has no activity against HDAC class II. Zabadinostat has antitumor activity[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Zabadinostat | 99.83% | Zabadinostat (CXD101) is a potent, selective and orally active class I HDAC inhibitor with IC50s of 63 nM, 570 nM and 550 nM for HDAC1, HDAC2 and HDAC3, respectively. Zabadinostat has no activity against HDAC class II. Zabadinostat has antitumor activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Zabadinostat (Standard) | ≥98% | Zabadinostat (Standard) is the analytical standard of Zabadinostat (HY-100748). This product is intended for research and analytical applications. Zabadinostat (CXD101) is a potent, selective and orally active class I HDAC inhibitor with IC50s of 63 nM, 570 nM and 550 nM for HDAC1, HDAC2 and HDAC3, respectively. Zabadinostat has no activity against HDAC class II. Zabadinostat has antitumor activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.56
HY-162487HDAC-IN-72 -
Similarity Score 0.56
HY-111048Corin -
Similarity Score 0.56
HY-144293HDAC-IN-31 -
Similarity Score 0.55
HY-120106BG14 -
Similarity Score 0.54
HY-110264MI-192 -
Similarity Score 0.54
HY-149817AChE-IN-29 -
Similarity Score 0.53
HY-164459AZ8010 -
Similarity Score 0.53
HY-183150HDAC1-IN-13 -
Similarity Score 0.53
HY-W326094Dinaline -
Explore the MedChemAI to find more analogs
References
- [1]. Eyre TA, et al. Predictive biomarkers for disease sensitivity in lymphoma - the holy grail for HDAC inhibitors? Oncotarget. 2018 Dec 18;9(99):37280-37281. [Content Brief]
- [2]. Eyre TA, et al. A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. Cancer. 2019 Jan 1;125(1):99-108. [Content Brief]
